FDA approves clinical study of tradipitant in the treatment of severe COVID-19 pneumonia

The Phase III double-blind, placebo-controlled study will investigate the safety and efficacy of the investigational neurokinin-1 receptor antagonist in the treatment of around 300 adults with inflammatory lung injury associated with severe COVID-19 infection.


Biospace Inc.